{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Bette S"],"pubmed_abstract":["<h4>Introduction</h4>Istradefylline offers a novel mechanism (adenosine A<sub>2A</sub> receptor antagonism) to treat OFF episodes in Parkinson's disease (PD). It may potentially offer improved tolerability versus other adjuncts, but comparative safety data are lacking.<h4>Methods</h4>A systematic review and Bayesian network <i>meta</i>-analysis (NMA) incorporating RCTs of PD adjuncts until January 10, 2024, was conducted to estimate relative safety. Inconsistency was assessed and heterogeneity evaluated by global I<sup>2</sup>-statistic and between-study heterogeneity. Incidences of safety outcomes were summarized from RWE identified according to the same criteria.<h4>Results</h4>100 RCTs and 55 RWE publications were identified; 76 RCTs were included in NMAs. Istradefylline demonstrated lo"],"journal":["Clinical parkinsonism & related disorders"],"pagination":["100307"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11904592"],"repository":["biostudies-literature"],"pubmed_title":["Comparative safety of istradefylline in Parkinson's disease: A systematic review of randomized controlled trials and real-world studies."],"pmcid":["PMC11904592"],"pubmed_authors":["Qian J","Thai A","Batson S","Shinoda K","Bette S","Shimoda H","Cummings H","Truong D","Redhead G","Hodkinson A"],"additional_accession":[]},"is_claimable":false,"name":"Comparative safety of istradefylline in Parkinson's disease: A systematic review of randomized controlled trials and real-world studies.","description":"<h4>Introduction</h4>Istradefylline offers a novel mechanism (adenosine A<sub>2A</sub> receptor antagonism) to treat OFF episodes in Parkinson's disease (PD). It may potentially offer improved tolerability versus other adjuncts, but comparative safety data are lacking.<h4>Methods</h4>A systematic review and Bayesian network <i>meta</i>-analysis (NMA) incorporating RCTs of PD adjuncts until January 10, 2024, was conducted to estimate relative safety. Inconsistency was assessed and heterogeneity evaluated by global I<sup>2</sup>-statistic and between-study heterogeneity. Incidences of safety outcomes were summarized from RWE identified according to the same criteria.<h4>Results</h4>100 RCTs and 55 RWE publications were identified; 76 RCTs were included in NMAs. Istradefylline demonstrated lo","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2025-04-26T05:46:59.88Z","creation":"2025-04-06T11:40:41.695Z"},"accession":"S-EPMC11904592","cross_references":{"pubmed":["40084346"],"doi":["10.1016/j.prdoa.2025.100307"]}}